Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Sep;36(9):1799–1804. doi: 10.1128/aac.36.9.1799

In vitro models for studying toxicity of antifungal agents.

V Joly 1, J Bolard 1, P Yeni 1
PMCID: PMC192189  PMID: 1416870

Full text

PDF
1804

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Binet A., Bolard J. Recovery of hepatocytes from attack by the pore former amphotericin B. Biochem J. 1988 Jul 15;253(2):435–440. doi: 10.1042/bj2530435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boggs J. M., Chang N. H., Goundalkar A. Liposomal amphotericin B inhibits in vitro T-lymphocyte response to antigen. Antimicrob Agents Chemother. 1991 May;35(5):879–885. doi: 10.1128/aac.35.5.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta. 1986 Dec 22;864(3-4):257–304. doi: 10.1016/0304-4157(86)90002-x. [DOI] [PubMed] [Google Scholar]
  4. Bolard J., Legrand P., Heitz F., Cybulska B. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry. 1991 Jun 11;30(23):5707–5715. doi: 10.1021/bi00237a011. [DOI] [PubMed] [Google Scholar]
  5. Brajtburg J., Elberg S., Kobayashi G. S., Medoff G. Toxicity and induction of resistance to Listeria monocytogenes infection by amphotericin B in inbred strains of mice. Infect Immun. 1986 Nov;54(2):303–307. doi: 10.1128/iai.54.2.303-307.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brajtburg J., Elberg S., Schwartz D. R., Vertut-Croquin A., Schlessinger D., Kobayashi G. S., Medoff G. Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B. Antimicrob Agents Chemother. 1985 Feb;27(2):172–176. doi: 10.1128/aac.27.2.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brajtburg J., Medoff G., Kobayashi G. S., Elberg S., Finegold C. Permeabilizing and hemolytic action of large and small polyene antibiotics on human erythrocytes. Antimicrob Agents Chemother. 1980 Oct;18(4):586–592. doi: 10.1128/aac.18.4.586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brajtburg J., Powderly W. G., Kobayashi G. S., Medoff G. Amphotericin B: delivery systems. Antimicrob Agents Chemother. 1990 Mar;34(3):381–384. doi: 10.1128/aac.34.3.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Capasso G., Schuetz H., Vickermann B., Kinne R. Amphotericin B and amphotericin B methylester: effect on brush border membrane permeability. Kidney Int. 1986 Sep;30(3):311–317. doi: 10.1038/ki.1986.186. [DOI] [PubMed] [Google Scholar]
  10. Cheng J. T., Witty R. T., Robinson R. R., Yarger W. E. Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. Kidney Int. 1982 Dec;22(6):626–633. doi: 10.1038/ki.1982.221. [DOI] [PubMed] [Google Scholar]
  11. Collette N., van der Auwera P., Lopez A. P., Heymans C., Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother. 1989 Mar;33(3):362–368. doi: 10.1128/aac.33.3.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cordonnier C., Bernaudin J. F., Bierling P., Huet Y., Vernant J. P. Pulmonary complications occurring after allogeneic bone marrow transplantation. A study of 130 consecutive transplanted patients. Cancer. 1986 Sep 1;58(5):1047–1054. doi: 10.1002/1097-0142(19860901)58:5<1047::aid-cncr2820580512>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  13. Denning D. W., Tucker R. M., Hanson L. H., Hamilton J. R., Stevens D. A. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med. 1989 Oct;149(10):2301–2308. [PubMed] [Google Scholar]
  14. Fisher P. B., Goldstein N. I., Bonner D. P., Mechlinski W., Bryson V., Schaffner C. P. Toxicity of amphotericin B and its methyl ester toward normal and tumor cell lines. Cancer Res. 1975 Aug;35(8):1996–1999. [PubMed] [Google Scholar]
  15. Gerson S. L., Talbot G. H., Hurwitz S., Strom B. L., Lusk E. J., Cassileth P. A. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984 Mar;100(3):345–351. doi: 10.7326/0003-4819-100-3-345. [DOI] [PubMed] [Google Scholar]
  16. Henry-Toulmé N., Seman M., Bolard J. Interaction of amphotericin B and its N-fructosyl derivative with murine thymocytes: a comparative study using fluorescent membrane probes. Biochim Biophys Acta. 1989 Jul 10;982(2):245–252. doi: 10.1016/0005-2736(89)90061-8. [DOI] [PubMed] [Google Scholar]
  17. Hidaka K., Endo H., Akiyama S., Kuwano M. Isolation and characterization of amphotericin B-resistant cell lines in Chinese hamster cells. Cell. 1978 Jun;14(2):415–421. doi: 10.1016/0092-8674(78)90126-5. [DOI] [PubMed] [Google Scholar]
  18. Holleran W. M., Wilbur J. R., DeGregorio M. W. Empiric amphotericin B therapy in patients with acute leukemia. Rev Infect Dis. 1985 Sep-Oct;7(5):619–624. doi: 10.1093/clinids/7.5.619. [DOI] [PubMed] [Google Scholar]
  19. Jefcoate C. R. Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. Methods Enzymol. 1978;52:258–279. doi: 10.1016/s0076-6879(78)52029-6. [DOI] [PubMed] [Google Scholar]
  20. Joly V., Bolard J., Saint-Julien L., Carbon C., Yeni P. Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations. Antimicrob Agents Chemother. 1992 Feb;36(2):262–266. doi: 10.1128/aac.36.2.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Joly V., Dromer F., Barge J., Yeni P., Seta N., Molas G., Carbon C. Incorporation of amphotericin B (AMB) into liposomes alters AMB-induced acute nephrotoxicity in rabbits. J Pharmacol Exp Ther. 1989 Oct;251(1):311–316. [PubMed] [Google Scholar]
  22. Joly V., Saint-Julien L., Carbon C., Yeni P. Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture. J Pharmacol Exp Ther. 1990 Oct;255(1):17–22. [PubMed] [Google Scholar]
  23. Joly V., Saint-Pierre-Chazalet M., Saint-Julien L., Bolard J., Carbon C., Yeni P. Inhibiting cholesterol synthesis reduces the binding and toxicity of amphotericin B against rabbit renal tubular cells in primary culture. J Infect Dis. 1992 Feb;165(2):337–343. doi: 10.1093/infdis/165.2.337. [DOI] [PubMed] [Google Scholar]
  24. Juliano R. L., Grant C. W., Barber K. R., Kalp M. A. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol. 1987 Jan;31(1):1–11. [PubMed] [Google Scholar]
  25. Jullien S., Brajtburg J., Bolard J. Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations. Biochim Biophys Acta. 1990 Jan 15;1021(1):39–45. doi: 10.1016/0005-2736(90)90381-w. [DOI] [PubMed] [Google Scholar]
  26. Jullien S., Contrepois A., Sligh J. E., Domart Y., Yeni P., Brajtburg J., Medoff G., Bolard J. Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids. Antimicrob Agents Chemother. 1989 Mar;33(3):345–349. doi: 10.1128/aac.33.3.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Jullien S., Vertut-Croquin A., Brajtburg J., Bolard J. Circular dichroism for the determination of amphotericin B binding to liposomes. Anal Biochem. 1988 Jul;172(1):197–202. doi: 10.1016/0003-2697(88)90432-0. [DOI] [PubMed] [Google Scholar]
  28. Kempen H. J., van Son K., Cohen L. H., Griffioen M., Verboom H., Havekes L. Effect of ketoconazole on cholesterol synthesis and on HMG-CoA reductase and LDL-receptor activities in Hep G2 cells. Biochem Pharmacol. 1987 Apr 15;36(8):1245–1249. doi: 10.1016/0006-2952(87)90077-3. [DOI] [PubMed] [Google Scholar]
  29. Kraemer F. B., Pont A. Inhibition of cholesterol synthesis by ketoconazole. Am J Med. 1986 Apr;80(4):616–622. doi: 10.1016/0002-9343(86)90816-8. [DOI] [PubMed] [Google Scholar]
  30. Krause H. J., Juliano R. L. Interactions of liposome-incorporated amphotericin B with kidney epithelial cell cultures. Mol Pharmacol. 1988 Sep;34(3):286–297. [PubMed] [Google Scholar]
  31. Lamy-Freund M. T., Ferreira V. F., Schreier S. Mechanism of inactivation of the polyene antibiotic amphotericin B. Evidence for radical formation in the process of autooxidation. J Antibiot (Tokyo) 1985 Jun;38(6):753–757. doi: 10.7164/antibiotics.38.753. [DOI] [PubMed] [Google Scholar]
  32. Longuet P., Joly V., Amirault P., Seta N., Carbon C., Yeni P. Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats. Antimicrob Agents Chemother. 1991 Jul;35(7):1303–1308. doi: 10.1128/aac.35.7.1303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Mehta R. T., Mehta K., Lopez-Berestein G., Juliano R. L. Effect of liposomal amphotericin B on murine macrophages and lymphocytes. Infect Immun. 1985 Feb;47(2):429–433. doi: 10.1128/iai.47.2.429-433.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Perfect J. R., Savani D. V., Durack D. T. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother. 1986 Apr;29(4):579–583. doi: 10.1128/aac.29.4.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Pont A., Williams P. L., Loose D. S., Feldman D., Reitz R. E., Bochra C., Stevens D. A. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982 Sep;97(3):370–372. doi: 10.7326/0003-4819-97-3-370. [DOI] [PubMed] [Google Scholar]
  36. Prendergast F. G., Haugland R. P., Callahan P. J. 1-[4-(Trimethylamino)phenyl]-6-phenylhexa-1,3,5-triene: synthesis, fluorescence properties, and use as a fluorescence probe of lipid bilayers. Biochemistry. 1981 Dec 22;20(26):7333–7338. doi: 10.1021/bi00529a002. [DOI] [PubMed] [Google Scholar]
  37. Princen H. M., Huijsmans C. M., Kuipers F., Vonk R. J., Kempen H. J. Ketoconazole blocks bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat by inhibiting cholesterol 7 alpha-hydroxylase. J Clin Invest. 1986 Oct;78(4):1064–1071. doi: 10.1172/JCI112662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Racis S. P., Plescia O. J., Geller H. M., Schaffner C. P. Comparative toxicities of amphotericin B and its monomethyl ester derivative on glial cells in culture. Antimicrob Agents Chemother. 1990 Jul;34(7):1360–1365. doi: 10.1128/aac.34.7.1360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Sawaya B. P., Weihprecht H., Campbell W. R., Lorenz J. N., Webb R. C., Briggs J. P., Schnermann J. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest. 1991 Jun;87(6):2097–2107. doi: 10.1172/JCI115240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Sheets J. J., Mason J. I. Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver. Drug Metab Dispos. 1984 Sep-Oct;12(5):603–606. [PubMed] [Google Scholar]
  41. Shirley S. F., Little J. R. Immunopotentiating effects of amphotericin B. II. Enhanced in vitro proliferative responses of murine lymphocytes. J Immunol. 1979 Dec;123(6):2883–2889. [PubMed] [Google Scholar]
  42. Sono H., Sonoda Y., Sato Y. Purification and characterization of cytochrome P-45014DM (lanosterol 14 alpha-demethylase) from pig liver microsomes. Biochim Biophys Acta. 1991 Jul 12;1078(3):388–394. doi: 10.1016/0167-4838(91)90161-r. [DOI] [PubMed] [Google Scholar]
  43. Stewart S. J., Spagnuolo P. J., Ellner J. J. Generation of suppressor T lymphocytes and monocytes by amphotericin B. J Immunol. 1981 Jul;127(1):135–139. [PubMed] [Google Scholar]
  44. Sugar A. M., Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Oct;85(4):481–489. doi: 10.1016/s0002-9343(88)80082-2. [DOI] [PubMed] [Google Scholar]
  45. Szoka F. C., Jr, Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother. 1987 Mar;31(3):421–429. doi: 10.1128/aac.31.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Van Cutsem J., Van Gerven F., Janssen P. A. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S15–S32. doi: 10.1093/clinids/9.supplement_1.s15. [DOI] [PubMed] [Google Scholar]
  47. Van den Bossche H., Willemsens G., Cools W., Cornelissen F., Lauwers W. F., van Cutsem J. M. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother. 1980 Jun;17(6):922–928. doi: 10.1128/aac.17.6.922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Vanden Bossche H., Marichal P., Gorrens J., Coene M. C., Willemsens G., Bellens D., Roels I., Moereels H., Janssen P. A. Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Mycoses. 1989;32 (Suppl 1):35–52. doi: 10.1111/j.1439-0507.1989.tb02293.x. [DOI] [PubMed] [Google Scholar]
  49. Vertut-Croquin A., Bolard J., Chabbert M., Gary-Bobo C. Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol- or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study. Biochemistry. 1983 Jun 7;22(12):2939–2944. doi: 10.1021/bi00281a024. [DOI] [PubMed] [Google Scholar]
  50. Vertut-Croquin A., Bolard J., Gary-Bobo C. M. Transfer of amphotericin B from gel state vesicles to mycoplasma cells: biphasic action on potassium transport and permeability. Antimicrob Agents Chemother. 1985 Aug;28(2):167–171. doi: 10.1128/aac.28.2.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Vertut-Croquin A., Brajtburg J., Medoff G. Two mechanisms of synergism when amphotericin B is used in combination with actinomycin D or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea against the human promyelocytic leukemia cell line HL-60. Cancer Res. 1986 Dec;46(12 Pt 1):6054–6058. [PubMed] [Google Scholar]
  52. Vertut-Doi A., Hannaert P., Bolard J. The polyene antibiotic amphotericin B inhibits the Na+/K+ pump of human erythrocytes. Biochem Biophys Res Commun. 1988 Dec 15;157(2):692–697. doi: 10.1016/s0006-291x(88)80305-x. [DOI] [PubMed] [Google Scholar]
  53. Walls E. V., Kay J. E. Inhibition of proliferation of a murine myeloma cell line and mitogen-stimulated B lymphocytes by the antibiotic amphotericin B (Fungizone). Immunology. 1982 Sep;47(1):115–121. [PMC free article] [PubMed] [Google Scholar]
  54. Young L. S. Nosocomial infections in the immunocompromised adult. Am J Med. 1981 Feb;70(2):398–404. doi: 10.1016/0002-9343(81)90779-8. [DOI] [PubMed] [Google Scholar]
  55. Zuger A., Louie E., Holzman R. S., Simberkoff M. S., Rahal J. J. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med. 1986 Feb;104(2):234–240. doi: 10.7326/0003-4819-104-2-234. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES